StonvexLoading…
StonvexStonvexStonvexCore line items from DDS's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q3 2026 (Est.) Expected 2026-08-10 | Annual 2026 2026-01-31 | Q4 2025 2025-11-01 | Q3 2025 2025-08-02 | Q2 2025 2025-05-03 |
|---|---|---|---|---|---|
Revenue | $1.54B | $6.47B | $4.51B | $3.04B | $1.53B |
Operating Income | Not available | $694.48M | $477.09M | $308.28M | $213.70M |
Net Income | Not available | $570.19M | $366.46M | $236.65M | $163.82M |
EPS (Diluted) | $4.10 | $36.42 | $23.39 | $15.08 | $10.39 |
Total Assets | Not available | $3.51B | $4.30B | $3.68B | $3.91B |
Total Liabilities | Not available | Not available | Not available | Not available | Not available |
Cash & Equivalents | Not available | $861.46M | $1.15B | $1.01B | $900.50M |
Free Cash Flow OCF − CapEx | Not available | $623.63M | $432.02M | $275.87M | $215.78M |
Shares Outstanding | Not available | 15.65K | 15.67M | 15.70M | 15.77M |